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Introduction and aim: Patient quality of life (QOL) while on long-term oral anticoagulant
therapy has been receiving greater attention in recent years due to the increase in life
expectancy brought about by advances in medical care. This study aimed to compare the
QOL, treatment satisfaction, hospitalization and bleeding rate in patients on long-term
warfarin versus direct oral anticoagulants (DOAC).
Methods: This was a cross-sectional study of patients with non-valvular atrial fibrillation
(NVAF) or venous thromboembolism (VTE) on long-term anticoagulant therapy attending
the cardiology clinic and anticoagulation clinic of the University Malaya Medical Centre
from July 1, 2016, to June 30, 2018. Patient QOL was assessed by using the Short Form 12
Health Survey (SF12), while treatment satisfaction was assessed by using the Perception of
Anticoagulation Treatment Questionnaire 2 (PACT-Q2).
Results: A total of 208 patients were recruited; 52.4% received warfarin and 47.6% received
DOAC. There was no significant difference in QOL between warfarin and DOAC based on
SF12 (physical QOL, P=0.083; mental QOL, P=0.665). Nevertheless, patients in the DOAC
group were significantly more satisfied with their treatment compared to the warfarin group
based on PACT-Q2 (P=0.004). The hospitalisation rate was significantly higher in the
warfarin group than the DOAC group (15.6% versus 3.0%, P=0.002). Clinically relevant
minor bleeds and severe bleeding events were non-significantly higher in the warfarin group
than the DOAC group (66.7% versus 40.0%, P=0.069).
Conclusion: Compared to warfarin, treatment of NVAF and VTE with DOAC showed
comparable QOL, higher treatment satisfaction, lesser hospitalization, and a non-significant
trend toward fewer bleeding episodes.
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Introduction
Warfarin, a vitamin K antagonist, has been widely used for decades to treat or
prevent stroke and systemic embolism in patients with atrial fibrillation (AF) or
venous thromboembolism (VTE). Warfarin has narrow therapeutic index, which
requires frequent international normalized ratio (INR) monitoring to prevent bleed-
ing complications and to maintain therapeutic efficacy. The target range of INR
may vary depending on the indications for anticoagulation.1,2 The use of warfarin is
challenging, as there is considerable interpatient variability in the daily maintenance
dose of warfarin. In addition, numerous foods and drugs as well as alcohol are
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